Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genes and mechanisms regulated by androgens as possible contributors to the male excess observed in autism [LNCaP]

ABSTRACT: We optimized ChIP-sequencing protocole and anti-androgen receptor (AR) antibodies on human prostate cancer cell line (LNCaP) after either DMSO (solvent) or DHT 100nM 4 hours treatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE86456 | GEO | 2018/02/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genes and mechanisms regulated by androgens as possible contributors to the male excess observed in autism [hNSCs]

Project description:We analyzed androgen receptor (AR) target genes on human neural stem cells (hNSCs) by ChIP-sequencing of AR IP after either DMSO (solvent), Testosterone 100nM, DHT 10 or 100nM 4 hours treatment in order to find the role of AR during brain development.

2018-02-01 | GSE86454 | GEO

Genes and pathways regulated by androgens as possible contributors to the male excess observed in autism [RNA-Seq]

Project description:We analyzed androgens effects on human neural stem cells (hNSCs) by RNA-sequencing after either DMSO (solvent), DHT 100nM, 10nM, Testosterone 100nM, 10nM, R1881 1nM or retinoic acid 1µM 24 hours treatment in order to find the role of androgen receptor (AR) during brain development.

2018-02-01 | GSE86457 | GEO

Genes and mechanisms regulated by androgens as possible contributors to the male excess observed in autism

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-02-01 | GSE86458 | GEO

Genes and mechanisms regulated by androgens as possible contributors to the male excess observed in autism

Project description:Genes and mechanisms regulated by androgens as possible contributors to the male excess observed in autism

| PRJNA341954 | ENA

Androgen receptor-coregulators hormone responsiveness LNCaP / GSF

Project description:The text description is: LNCaP are androgen receptor expressing prostate carcinoma cells. Genital skin fibroblasts also express the androgen receptor. Cells were either proliferating or they were G0-arrested. Treatment of cells was performed with either the androgen DHT (dihydrotestosterone), the androgen analogue R1881 (methyltrienolone), or the solvent ethanol. Some hybridizations were performed in the type 1 design. In these cases, the hormone treated sample was hybridized against the ethanol treated sample on the same microarray. Hormone mediated induction or repression of gene transcription can directly be deduced from R/G normalized ratios on arrays. For other experiments, the ethanol treated control and the hormone treated experiment were hybridized on separate microarrays against a common reference of RNA. This reference was composed out of common reference batch CRG (50%) and a fibroblast RNA (50%). This reference was called mixed reference. For all experiments, the same batch of mixed reference was used. A compound treatment design type is where the response to administration of a compound or chemical (including biological compounds such as hormones) is assayed. Compound Based Treatment: Ethanol, R1881 (methyltrienolone), or DHT (dihydrotestosterone) Cell Line: LNCaP (prostate cancer) or foreskin fibroblasts Culture Synchrony: proliferation / Go-arrest Keywords: compound_treatment_design

2006-10-12 | GSE4454 | GEO

Androgen receptor-coregulators hormone responsiveness LNCaP / GSF

2010-07-01 | E-GEOD-4454 | biostudies-arrayexpress

Contributors to excess infant mortality in the U.S. South.

Project description:BackgroundInfant mortality rates (IMRs) are disproportionally high in the U.S. South; however, the proximate contributors that could inform regional action remain unclear.PurposeTo quantify the components of excess infant mortality in the U.S. South by maternal race/ethnicity, underlying cause of death, and gestational age.MethodsU.S. Period Linked Birth/Infant Death Data Files 2007-2009 (analyzed in 2013) were used to compare IMRs between the South (U.S. Public Health Regions IV and VI) and all other regions combined.ResultsCompared to other regions, there were 1.18 excess infant deaths per 1000 live births in the South, representing about 1600 excess infant deaths annually. New Mexico and Texas did not have elevated IMRs relative to other regions; excess death rates among other states ranged from 0.62 per 1000 in Kentucky to 3.82 per 1000 in Mississippi. Racial/ethnic compositional differences, generally the greater proportion of non-Hispanic black births in the South, explained 59% of the overall regional difference; the remainder was mostly explained by higher IMRs among non-Hispanic whites. The leading causes of excess Southern infant mortality were sudden unexpected infant death (SUID; 36%, range=12% in Florida to 90% in Kentucky) and preterm-related death (22%, range= -71% in Kentucky to 51% in North Carolina). Higher rates of preterm birth, predominantly <34 weeks, accounted for most of the preterm contribution.ConclusionsTo reduce excess Southern infant mortality, comprehensive strategies addressing SUID and preterm birth prevention for both non-Hispanic black and white births are needed, with state-level findings used to tailor state-specific efforts.

| S-EPMC4545212 | biostudies-literature

DHT-dependent AR activity in LNCaP cells

Project description:AR transcriptional activity is regulated by DHT

2016-03-15 | GSE60721 | GEO

RNA sequencing of LNCaP cells treated with castration and/or enzalutamide

Project description:The goal of this study was to determine how androgen receptor inhibition alters transcriptional programs in prostate cancer cells. LNCaP prostate cancer cells were grown in 10% charcoal-stripped serum (CSS) supplemented with 0.5 nanomolar dihydrotestosterone (DHT), in CSS without DHT modeling castration, with CSS + DHT but in the presence of 10 micromolar enzalutamide, or in CSS without DHT (castrated) and in the presence of enzalutamide for 72 hours. Analysis shows that androgen receptor target genes are reduced with castration, enzalutamide or the combination of castration + enzalutamide.

2022-05-12 | GSE202755 | GEO

Transcription profiling of human androgen receptor expressing prostate carcinoma cell line LNCaP and normal human foreskin fibroblasts expressing the androgen receptor treated with dihydrotestosterone (DHT), ethanol, or untreated vs. a common reference, see E-SMDB-3637

Project description:LNCaP cells are an established androgen receptor expressing prostate carcinoma cell line. Human foreskin fibroblasts also expressing the androgen receptor were obtained from phenotypic normal male individuals. Cells were cultured either at confluency leading to G0 cell cycle state or while they were proliferating. Cells were either untreated, or treated with dihydrotestosterone (DHT) or ethanol (ETOH) which also served as the solvent for the DHT. All experimental RNA samples derived from the untreated or treated cell lines were hybridized on cDNA arrays against a common reference. This reference was composed out of common reference CRG (50%) and out of fibroblast RNA (50%). This reference is also called "mixed reference" in the description of the 26 individual experiments.

2006-11-06 | E-SMDB-3636 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data